Answers are grounded in this paper and cite their sources.
Comparative analysis reveals CXCL9 as a prognostic marker for inflammation in ILD and COPD, implying distinct treatment approaches.
CXCL9 levels correlate with divergent roles in ILD and COPD. It may serve as a prognostic marker, identifying treatable inflammation in ILD and inflammatory burden in COPD.
No takes yet. Share an insight, caveat, or question.
Yin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: